Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYBR CyberCare the new look of healthcare -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (2251)	6/19/2000 3:25:00 PM
From: sommovigo	Respond to of 3392

Kevin - if that is so then I retract my comments as they relate to that consideration alone. However, the "punishment" from the FDA for that kind of rule-breaking is simply a letter asking them nicely to stop. Since that kind of letter is no longer necessary, since they no longer have to stop marketing their equipment under the pre-FDA auspices, there will probably be no letter of reprimand. But it doesn't much matter if there is - or if there were one before FDA approval... it is just not a serious enough offense to the FDA - their punishment process is merely a formality with no fines or other actions.